(ORDO NEWS) — In 2003, a special vaccine against SARS (SARS) was developed, which was quite cheap. In a short period of time, it was slightly changed in order to be able to fight the SARS-CoV-2 coronavirus.But the vaccine was not used, as its creators did not receive any support or the necessary funding.
The CORBEVAX vaccine was developed in 2003. It was then that a rather serious outbreak of SARS occurred, which provoked the emergence of a slightly different type of coronavirus, different from Covid-19.
At the same time, experts note that even in the fight against SARS-CoV-2 with the help of the drug, a fairly high rate of effectiveness could be obtained. At the same time, its advantage is that it has a lower cost than all other analogues, so it is available to more people who would like to get vaccinated and feel safe.
Today, booster vaccinations have already begun in some countries, and proposals for a fourth dose are still being made in some countries.
At the same time, some poor countries cannot provide people with even the minimum number of vaccinations. Maureen Ferrand of the Rochester Institute of Technology believes that the drug, created in 2003, could significantly increase access to the drug for those who need it today.
The first drug CORBEVAX was developed by Maria Elena Bottazzi and Peter Hotez of the private college Baylor College of Medicine, which is located in Houston. At that time, an epidemic of SARS began to spread, but it did not last long, so everyone quickly forgot about the medicine.
In 2019, the spike protein in the vaccine was changed so that it provokes an immune response in the body. After that, it could be used to fight Covid-19. But this development did not interest the US government, so they did not finance further work on the vaccine.
It is worth paying attention to the fact that scientists did not want to get rich at the expense of their vaccine. They repeatedly said that they would like absolutely all people to have access to the medicine.
—
Online:
Contact us: [email protected]
Our Standards, Terms of Use: Standard Terms And Conditions.